| Development of Vaccines Against Respiratory Infections by Virulent Francisella tularensis
| DTRA (subcontract)
|
| Development of a Listeria monocytogenes-Based Therapeutic HBV Vaccine | NIH/NIAID SBIR Phase I
|
Listeria-Based Therapeutic Cancer Vaccine for Melanoma
| NIH/NCI SBIR Phase I
|
| Listeria-Based Vaccines for Ovarian Cancer Therapy | NIH/NCI SBIR Phase I |
| Use of Listeria as Colon Cancer Vaccine Adjuvants | NIH/NCI SBIR Phase I |
| Listeria-CEA Vaccine-Infected DC for Cancer Therapy | NIH/NCI SBIR Phase I |
| Novel Safe and Effective Vaccines for Biodefense and Cancer | USAMRAA (DoD) |
| Listeria-Based Ovarian Cancer Polyepitope Vaccines | NIH SBIR Phase I |
| Psoralen-Killed, Metabolically Active Anthrax Vaccine | NIAID |
| Listeria Immunotherapy for Pancreatic and Ovarian Cancer | NIH SBIR Phase II |
| Novel Safe and Effective Vaccines for Biodefense and Cancer (Mol Switch Vaccine) | USAMRAA (DoD) |
| Development of Listeria-Based Clinical Consensus HCV Vaccine Candidates | NIAID |
| Construct six stocks of Listeria monocytogenes (Lm)-based Vaccine Strains Encoding HIV-Gag or SIV-Gag Antigens | The Collaboration for AIDS Vaccine Discovery (CAVD) |
| Listeria monocytogenes-Based Vaccines Targeting Plasmodium falciparum Pre-Erythrocytic Stage Antigens | Malaria Vaccine Initiative |
| Development of Molecular Switch Vaccine - HCV KBMA | USAMRAA (DoD) |
| Tularemia Vaccine Development Team | NIAID Contract Grant |